Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript Summary
Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript Summary
Non-GAAP operating margin increased approximately 2 percentage points sequentially to minus 6%.The following is a summary of the Fulgent Genetics, Inc. (FLGT) Q3 2024 Earnings Call Transcript:
以下是Fulgent Genetics, Inc. (FLGT) 2024年第三季度業績會交易摘要：
Financial Performance:
財務表現:
Total Q3 revenue was $71.7 million, a decrease from $84.7 million in the third quarter of 2023.
GAAP gross margin was 37.3%, with a non-GAAP gross margin of 40%.
Non-GAAP operating margin increased approximately 2 percentage points sequentially to minus 6%.
Adjusted EBITDA income for Q3 was approximately $400,000, compared to an income of $18.1 million in Q3 2023.
Projected improvement in GAAP EPS loss from $1.95 to approximately $1.70 per share for the full year.
第三季度總營業收入爲7170萬美元，低於2023年第三季度的8470萬美元。
根據GAAP，毛利率爲37.3％，非GAAP毛利率爲40％。
非GAAP營業利潤率按季度增加約2個百分點，達到-6％。
第三季度調整後的EBITDA收入約爲40萬美元，較2023年第三季度的1810萬美元有所增加。
預計全年GAAP每股虧損從1.95美元降至約1.70美元。
Business Progress:
業務進展：
Expanded carrier screening and hereditary cancer screening tests are in high demand.
Established a new $99 million contract over five years with VA hospitals for hereditary cancer and other germline tests.
Introduced KNOVA, a novel NIPT test, and received MoIDX approval for multiple hereditary cancer panels in the third quarter.
擴大的攜帶者篩查和遺傳性癌症篩查測試需求很高。
與VA醫院達成了一項新的價值9900萬美元的合同，爲遺傳性癌症和其他生殖系列測試服務五年。
推出了KNOVA，一種新型NIPt測試，並在第三季度獲得了MoIDX對多種遺傳性癌症面板的批准。
Opportunities:
機會：
Continued growth in core business areas: precision diagnostics, anatomic pathology, and pharma services.
The ability to further compete for biopharma service projects due to a larger test portfolio, including new platforms like 10x Genomics and Akoya.
Expanded presence in digital pathology, with 80% of slides digitized, enhancing operational efficiency and potential for integrating AI technologies in the future.
在覈心業務領域持續增長：精準診斷，解剖病理學和製藥服務。
由於測試組合更大，包括10x genomics和Akoya等新平台，能夠進一步競爭生物製藥服務項目。
在數字病理學領域擴大影響力，80%的幻燈片完成數字化，提高運營效率並增加將來整合人工智能技術的潛力。
Risks:
風險：
Revenue from COVID-19 testing is now negligible, implying a pivot to more sustainable core business offerings.
A projected operating margin of approximately minus 12% for the year highlights operational risks tied to investments for growth.
COVID-19測試的營業收入現在可以忽略不計，這意味着向更可持續的核心業務業務轉型。
預計全年營業利潤率約爲負12%，凸顯了與爲增長投資相關的運營風險。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
